Assessing the Predictive Accuracy of the AMAP Risk Score for Hepatocellular Carcinoma (HCC): Diagnostic Test Accuracy and Meta-analysis

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2024 Sep 12

PMID 39262566

Authors

Anas Elgenidy

Tareq M Abubasheer

Ramez M Odat

Mohamed G Abdelrahim

Nada S Jibril

Aya M Ramadan

Lujain Ballut

Mohamed E Haseeb

Abdelrahman Ragab

Almutasem M Ismail

Ahmed M Afifi

Benarad J Mohamed

Prasun K Jalal

Affiliations

Soon will be listed here.

Abstract

Purpose: We aimed to perform a meta-analysis with the intention of evaluating the reliability and test accuracy of the aMAP risk score in the identification of HCC.

Methods: A systematic search was performed in PubMed, Scopus, Cochrane, Embase, and Web of Science databases from inception to September 2023, to identify studies measuring the aMAP score in patients for the purpose of predicting the occurrence or recurrence of HCC. The meta-analysis was performed using the meta package in R version 4.1.0. The diagnostic accuracy meta-analysis was conducted using Meta-DiSc software.

Results: Thirty-five studies 102,959 participants were included in the review. The aMAP score was significantly higher in the HCC group than in the non-HCC group, with a mean difference of 6.15. When the aMAP score is at 50, the pooled sensitivity, specificity, negative likelihood ratio, and positive likelihood ratio with 95% CI was 0.961 (95% CI 0.936, 0.976), 0.344 (95% CI 0.227, 0.483), 0.114 (95% CI 0.087, 0.15), and 1.464 (95% CI 1.22, 1.756), respectively. At a cutoff value of 60, the pooled sensitivity, specificity, negative likelihood ratio, and positive likelihood ratio with 95% CI was 0.594 (95% CI 0.492, 0.689), 0.816 (95% CI 0.714, 0.888), 0.497 (95% CI 0.418, 0.591), and 3.235 (95% CI 2.284, 4.582), respectively.

Conclusion: The aMAP score is a reliable, accurate, and easy-to-use tool for predicting HCC patients of all stages, including early-stage HCC. Therefore, the aMAP score can be a valuable tool for surveillance of HCC patients and can help to improve early detection and reduce mortality.

References

Yang J, Addissie B, Mara K, Harmsen W, Dai J, Zhang N . GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2018; 28(3):531-538. PMC: 6401221. DOI: 10.1158/1055-9965.EPI-18-0281. View

Villa E, Donghia R, Baldaccini V, Tedesco C, Shahini E, Cozzolongo R . GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study. Hepatol Commun. 2023; 7(10). PMC: 10503687. DOI: 10.1097/HC9.0000000000000262. View

Singal A, Tayob N, Mehta A, Marrero J, Jin Q, Lau J . Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021; 20(4):953-955.e2. PMC: 8526617. DOI: 10.1016/j.cgh.2021.04.018. View

Yang T, Xing H, Wang G, Wang N, Liu M, Yan C . A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B. Clin Chem. 2019; 65(12):1543-1553. DOI: 10.1373/clinchem.2019.308965. View

Mao H, Zheng S, Yang S, Huang Z, Xue Y, Zhou M . A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study. PeerJ. 2023; 11:e15014. PMC: 10042153. DOI: 10.7717/peerj.15014. View

Shiha G, Mikhail N, Soliman R . External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs. J Hepatol. 2020; 74(4):994-996. DOI: 10.1016/j.jhep.2020.10.008. View

Xin Y, Zhang X, Yang Y, Chen Y, Wang Y, Zhou X . Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study. J Gastrointest Oncol. 2022; 12(6):2930-2942. PMC: 8748026. DOI: 10.21037/jgo-21-506. View

Tayob N, Christie I, Richardson P, Feng Z, White D, Davila J . Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2018; 17(9):1886-1893.e5. PMC: 6570589. DOI: 10.1016/j.cgh.2018.12.005. View

Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y . JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2015; 3(3-4):458-68. PMC: 4531423. DOI: 10.1159/000343875. View

10.

Kansagara D, Papak J, Pasha A, ONeil M, Freeman M, Relevo R . Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014; 161(4):261-9. DOI: 10.7326/M14-0558. View

11.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

12.

Innes H, Hamill V, McDonald S, Hayes P, Johnson P, Dillon J . Comparing Predicted Probability of Hepatocellular Carcinoma in Patients With Cirrhosis With the General Population: An Opportunity to Improve Risk Communication?. Am J Gastroenterol. 2022; 117(9):1454-1461. DOI: 10.14309/ajg.0000000000001879. View

13.

Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D . Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev. 2021; 10:CD013362. PMC: 8493329. DOI: 10.1002/14651858.CD013362.pub2. View

14.

Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q . Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma. 2021; 8:837-850. PMC: 8327363. DOI: 10.2147/JHC.S308587. View

15.

Carr B, Guerra V, Giannini E, Farinati F, Ciccarese F, Rapaccini G . Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers. 2014; 29(3):e215-23. DOI: 10.5301/jbm.5000064. View

16.

Sun Y, Li Z, Liao G, Xia M, Xu X, Cai S . aMAP Score as a Predictor for Long-Term Outcomes in Patients with HBV-Related Acute-on-Chronic Liver Failure. Int J Gen Med. 2022; 15:407-415. PMC: 8759991. DOI: 10.2147/IJGM.S343457. View

17.

McGlynn K, Petrick J, London W . Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2):223-38. PMC: 4712629. DOI: 10.1016/j.cld.2015.01.001. View

18.

Inoue J, Kobayashi T, Akahane T, Kimura O, Sato K, Ninomiya M . Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study. J Clin Med. 2022; 11(9). PMC: 9101732. DOI: 10.3390/jcm11092354. View

19.

Fan R, Niu J, Ma H, Xie Q, Cheng J, Rao H . Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. Aliment Pharmacol Ther. 2021; 54(3):329-338. DOI: 10.1111/apt.16469. View

20.

Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q . aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020; 73(6):1368-1378. DOI: 10.1016/j.jhep.2020.07.025. View